Reuters logo
BRIEF-ContraVir to highlight clinical data from phase 2a study of tenofovir exalidex for treating hepatitis B
February 14, 2017 / 11:11 AM / in 8 months

BRIEF-ContraVir to highlight clinical data from phase 2a study of tenofovir exalidex for treating hepatitis B

Feb 14 (Reuters) - ContraVir Pharmaceuticals Inc -

* ContraVir to highlight clinical data from ongoing phase 2a study of tenofovir exalidex (TXL) for treating hepatitis B

* TXL showed comparable antiviral activity to viread and continues to be safe and well tolerated by HBV patients in study Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below